Advertisement
Skip to Content

Intra-Cellular Therapies Inc ITCI Stock Quote

| Rating as of

NASDAQ: ITCI

Last close prices updated as of Feb 03, 2023, 4:00 PM EST | USD | BATS BZX Real-Time Price
  • Last Close 48.92
  • Sector Healthcare
  • Industry Drug Manufacturers - Specialty & Generic
  • Investment Style Small Growth
  • Day Range 48.29  –  49.81
  • Year Range 42.42  –  66.00
  • Market Cap 4.6330 Bil
  • Volume / Avg 573,096.0 /  572,050.2
  • Price / Sales 23.71
  • Price / Book 6.76
  • Forward Div Yield
  • Trailing Div Yield

Morningstar‘s Stock Analysis ITCI

Valuation
Currency in
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics ITCI

Company Profile ITCI

Business Description

Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.

Contact
430 East 29th Street
New York, NY, 10016
Industry Drug Manufacturers - Specialty & Generic
Employees 512

Related Articles ITCI

FAQs for Intra-Cellular Therapies Inc Stock

No. ITCI does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

ITCI’s market cap is 4.63 Bil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

ITCI’s stock style is Small Growth.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

Learn more about style.

ITCI’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare ITCI’s historical performance against its industry peers and the overall market.